Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2a, Multicenter, Open-label Study Evaluating ABI-H0731-Containing Regimens in Patients With Chronic Hepatitis B

Next Previous
X
Search
Trial Profile

A Randomized Phase 2a, Multicenter, Open-label Study Evaluating ABI-H0731-Containing Regimens in Patients With Chronic Hepatitis B

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entecavir (Primary) ; Peginterferon alfa (Primary) ; Vebicorvir (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Assembly Biosciences

    • Most Recent Events

    • 04 Oct 2023 Status changed to discontinued.
    • 24 Jun 2023 Results assessing the relative safety and efficacy of vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection, presented at the European Association for the Study of the Liver Congress 2023.
    • 21 Jun 2023 Results presented in an Assembly Biosciences media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top